Veru (VERU) Asset Writedowns and Impairment (2017 - 2025)
Veru (VERU) posted quarterly Asset Writedowns and Impairment of -$72831.0 for Q3 2025, down 124.22% year-over-year from $300663.0 in Q3 2024, and down 124.22% quarter-over-quarter from $300663.0 in Q3 2024.
Veru (VERU) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Veru (VERU) has reported Asset Writedowns and Impairment for 9 consecutive years, with -$72831.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Asset Writedowns and Impairment fell 124.22% year-over-year to -$72831.0; the TTM figure through Sep 2025 stood at $227832.0 (down 24.22% YoY), while the FY2025 annual figure was -$72831.0, down 104.65% from the prior year.
- Asset Writedowns and Impairment slipped to -$72831.0 in Q3 2025 per VERU's latest filing, from $300663.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $3.9 million in Q1 2023 and bottomed at -$72831.0 in Q3 2025.
- Historically, Asset Writedowns and Impairment has averaged $521744.1 across 5 years, with a median of $33375.0 in 2021.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment surged 195100.0% — and 2025, when it plunged 124.22%.
- Veru's Asset Writedowns and Impairment stood at $408418.0 in 2021, then sank by 100.49% to -$2000.0 in 2022, then soared by 195100.0% to $3.9 million in 2023, then tumbled by 92.29% to $300663.0 in 2024, then slumped by 124.22% to -$72831.0 in 2025.
- Business Quant data shows VERU's Asset Writedowns and Impairment at -$72831.0 in Q3 2025, $300663.0 in Q3 2024, and $3.9 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -72,831.00 |
| Sep 30, 2025 | -72,831.00 |
| Sep 30, 2024 | 300,663.00 |
| Sep 30, 2024 | 300,663.00 |
| Mar 31, 2023 | 3.90 Mn |
| Mar 31, 2023 | 3.90 Mn |
| Sep 30, 2022 | -2,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -2,500.00 |
| Jun 30, 2022 | -2,500.00 |
| Mar 31, 2022 | -2,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Sep 30, 2021 | 408,418.00 |
| Sep 30, 2021 | 408,418.00 |
| Jun 30, 2021 | 132,572.00 |
| Jun 30, 2021 | 132,572.00 |
| Mar 31, 2021 | 33,375.00 |
| Mar 31, 2021 | 33,375.00 |
| Dec 31, 2020 | 9,138.00 |
| Dec 31, 2020 | 9,138.00 |